Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dermategrity Anti-fecal Barrier Cream for Moisture Associated Skin Damage
NCT06221046Not yet recruiting
- Sponsor
- ScotiaDerm
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Modality
- Peptides, Small Molecules
01
Overview
Randomised, double-blind trial of Dermategrity Everyday Barrier Cream in Moisture-associated skin damage (MASD) and incontinence-associated dermatitis (IAD) (2 arms), sponsored by ScotiaDerm. Primary endpoints: Global Incontinence-Associated Dermatitis Clinical Assessment at 14 days, Visual Analog Scale for Erythema at 14 days and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Dermategrity Everyday Barrier Cream
03
Conditions
Moisture-associated skin damage (MASD)incontinence-associated dermatitis (IAD)
Beyond the preview
Go deeper on NCT06221046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221046.